Codexis up on licensing agreement with Aldevron

Codexis

14/12/2023 12:30

** Shares of enzyme engineering company Codexis  CDXS.O  up
about 12.4% at $2.4 premarket 
    ** Co entered into licensing agreement with Aldevron
    ** Aldevron, with the deal, will receive global
manufacturing and commercialization rights to CDXS' Hicap RNA
polymerase, called Codex
    ** Codexis will receive payments for near-term technical
milestones, along with commercial milestones and sales-based
royalties 
    ** RNA polymerase helps translate gentic code from DNA to
RNA, a key step in production of proteins needed for various
cellular functions 
    ** Codex has been uniquely engineered to produce synthetic
mRNA at high yield and low immunogenicity - company 
    ** Aldevron manufactures proteins, enzymes, and other key
components for the development of vaccines, gene, cell therapies
among other treatments 
    ** As of last close, CDXS stock down 55.2% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))